Logo image of AMRN

AMARIN CORP PLC -ADR (AMRN) Stock Fundamental Analysis

NASDAQ:AMRN - Nasdaq - US0231112063 - ADR - Currency: USD

0.594  +0 (+0.49%)

After market: 0.59 0 (-0.67%)

Fundamental Rating

3

Overall AMRN gets a fundamental rating of 3 out of 10. We evaluated AMRN against 571 industry peers in the Biotechnology industry. AMRN scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. AMRN is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year AMRN has reported negative net income.
In the past year AMRN has reported a negative cash flow from operations.
In the past 5 years AMRN reported 4 times negative net income.
In the past 5 years AMRN reported 4 times negative operating cash flow.
AMRN Yearly Net Income VS EBIT VS OCF VS FCFAMRN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -50M -100M -150M

1.2 Ratios

AMRN has a better Return On Assets (-5.24%) than 89.52% of its industry peers.
The Return On Equity of AMRN (-7.40%) is better than 91.30% of its industry peers.
Industry RankSector Rank
ROA -5.24%
ROE -7.4%
ROIC N/A
ROA(3y)-6.11%
ROA(5y)-4.55%
ROE(3y)-9.11%
ROE(5y)-6.78%
ROIC(3y)N/A
ROIC(5y)N/A
AMRN Yearly ROA, ROE, ROICAMRN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200 400 600 800

1.3 Margins

AMRN's Gross Margin of 56.46% is fine compared to the rest of the industry. AMRN outperforms 78.15% of its industry peers.
AMRN's Gross Margin has declined in the last couple of years.
AMRN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 56.46%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.31%
GM growth 5Y-2.63%
AMRN Yearly Profit, Operating, Gross MarginsAMRN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50 -50 -100 -150

More info and screens

6

2. Health

2.1 Basic Checks

AMRN does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for AMRN has been increased compared to 1 year ago.
Compared to 5 years ago, AMRN has more shares outstanding
AMRN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
AMRN Yearly Shares OutstandingAMRN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M
AMRN Yearly Total Debt VS Total AssetsAMRN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M 800M 1B

2.2 Solvency

Based on the Altman-Z score of -1.51, we must say that AMRN is in the distress zone and has some risk of bankruptcy.
AMRN has a Altman-Z score (-1.51) which is in line with its industry peers.
There is no outstanding debt for AMRN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -1.51
ROIC/WACCN/A
WACC7.13%
AMRN Yearly LT Debt VS Equity VS FCFAMRN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200M 400M 600M

2.3 Liquidity

A Current Ratio of 3.23 indicates that AMRN has no problem at all paying its short term obligations.
The Current ratio of AMRN (3.23) is worse than 62.17% of its industry peers.
A Quick Ratio of 2.11 indicates that AMRN has no problem at all paying its short term obligations.
AMRN has a worse Quick ratio (2.11) than 73.89% of its industry peers.
Industry RankSector Rank
Current Ratio 3.23
Quick Ratio 2.11
AMRN Yearly Current Assets VS Current LiabilitesAMRN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M 800M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 30.77% over the past year.
AMRN shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -25.26%.
Measured over the past years, AMRN shows a small growth in Revenue. The Revenue has been growing by 6.01% on average per year.
EPS 1Y (TTM)30.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-20%
Revenue 1Y (TTM)-25.26%
Revenue growth 3Y-20.64%
Revenue growth 5Y6.01%
Sales Q2Q%-35.97%

3.2 Future

Based on estimates for the next years, AMRN will show a very strong growth in Earnings Per Share. The EPS will grow by 38.30% on average per year.
The Revenue is expected to grow by 13.06% on average over the next years. This is quite good.
EPS Next Y-2%
EPS Next 2Y-25.64%
EPS Next 3Y-1.45%
EPS Next 5Y38.3%
Revenue Next Year-31.86%
Revenue Next 2Y-24.14%
Revenue Next 3Y-9.87%
Revenue Next 5Y13.06%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
AMRN Yearly Revenue VS EstimatesAMRN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 200M 400M 600M 800M
AMRN Yearly EPS VS EstimatesAMRN Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 0.5 -0.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for AMRN. In the last year negative earnings were reported.
Also next year AMRN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AMRN Price Earnings VS Forward Price EarningsAMRN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AMRN Per share dataAMRN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-25.64%
EPS Next 3Y-1.45%

More info and screens

0

5. Dividend

5.1 Amount

AMRN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AMARIN CORP PLC -ADR

NASDAQ:AMRN (2/20/2025, 8:00:00 PM)

After market: 0.59 0 (-0.67%)

0.594

+0 (+0.49%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-30 2024-10-30/amc
Earnings (Next)N/A N/A
Inst Owners19.76%
Inst Owner Change8.49%
Ins Owners1%
Ins Owner Change2.61%
Market Cap244.33M
Analysts42.5
Price Target1.02 (71.72%)
Short Float %4.16%
Short Ratio11.27
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)41.18%
Min EPS beat(2)-17.65%
Max EPS beat(2)100%
EPS beat(4)3
Avg EPS beat(4)46.08%
Min EPS beat(4)-17.65%
Max EPS beat(4)100%
EPS beat(8)4
Avg EPS beat(8)29.08%
EPS beat(12)6
Avg EPS beat(12)17.17%
EPS beat(16)10
Avg EPS beat(16)42.15%
Revenue beat(2)1
Avg Revenue beat(2)11.43%
Min Revenue beat(2)-6.83%
Max Revenue beat(2)29.69%
Revenue beat(4)2
Avg Revenue beat(4)8.7%
Min Revenue beat(4)-6.83%
Max Revenue beat(4)29.69%
Revenue beat(8)6
Avg Revenue beat(8)6.96%
Revenue beat(12)7
Avg Revenue beat(12)2.97%
Revenue beat(16)7
Avg Revenue beat(16)0.96%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)-2.44%
Revenue NQ rev (1m)-4.12%
Revenue NQ rev (3m)-4.12%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-2.42%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.01
P/FCF N/A
P/OCF N/A
P/B 0.46
P/tB 0.48
EV/EBITDA N/A
EPS(TTM)-0.09
EYN/A
EPS(NY)-0.22
Fwd EYN/A
FCF(TTM)-0.05
FCFYN/A
OCF(TTM)-0.04
OCFYN/A
SpS0.59
BVpS1.29
TBVpS1.25
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -5.24%
ROE -7.4%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 56.46%
FCFM N/A
ROA(3y)-6.11%
ROA(5y)-4.55%
ROE(3y)-9.11%
ROE(5y)-6.78%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.31%
GM growth 5Y-2.63%
F-Score4
Asset Turnover0.32
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 17.04%
Cap/Sales 0.21%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.23
Quick Ratio 2.11
Altman-Z -1.51
F-Score4
WACC7.13%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)30.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-20%
EPS Next Y-2%
EPS Next 2Y-25.64%
EPS Next 3Y-1.45%
EPS Next 5Y38.3%
Revenue 1Y (TTM)-25.26%
Revenue growth 3Y-20.64%
Revenue growth 5Y6.01%
Sales Q2Q%-35.97%
Revenue Next Year-31.86%
Revenue Next 2Y-24.14%
Revenue Next 3Y-9.87%
Revenue Next 5Y13.06%
EBIT growth 1Y-94.17%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year10.57%
EBIT Next 3Y16.55%
EBIT Next 5YN/A
FCF growth 1Y91.01%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y91.25%
OCF growth 3YN/A
OCF growth 5YN/A